AAV9-CAG-FLuc-2A-GFP

AAV9-CAG-FLuc-2A-GFP is a viral vector system that combines multiple advantageous features, making it suitable for advanced gene delivery applications. The AAV serotype 9 capsid exhibits excellent tropism to various tissue types, including liver, muscle, and the central nervous system, while also possessing low immunogenicity and long-term transgene expression. This vector utilizes the powerful synthetic CAG promoter (a hybrid of the CMV immediate early enhancer and the chicken β-actin promoter) to drive robust and widespread expression of two reporter genes. The innovative 2A self-cleaving peptide linker enables equimolar co-expression of firefly luciferase (FLuc) and green fluorescent protein (GFP), allowing for multimodal detection—FLuc for sensitive in vivo bioluminescence imaging and GFP for direct fluorescence visualization at cellular resolution. This dual-reporter system provides built-in validation through cross-verification of results while maintaining optimal expression levels of both transgenes through the efficient ribosomal skipping mechanism of the 2A sequence.

This versatile vector has broad applications across various research fields. In neuroscience, it enables non-invasive, long-term tracking of brain gene expression patterns via bioluminescence imaging, while also allowing for subsequent histological analysis using GFP fluorescence. In stem cell research, the system allows for simultaneous monitoring of cell fate (GFP) and functional integration (FLuc activity) in transplantation studies. In cancer research, it serves as an excellent tool for tumor modeling, enabling simultaneous in vivo tumor growth monitoring (FLuc) and in vitro metastasis detection (GFP). Furthermore, the AAV9 serotype''s ability to cross the blood-brain barrier makes this vector particularly well-suited for studying neurological disorders and developing therapies targeting the central nervous system.